Core Insights - United Therapeutics announced positive Phase 3 study results for nebulized Tyvaso, showing a reduction in clinical worsening of idiopathic pulmonary fibrosis (IPF) compared to a placebo, leading to a significant increase in stock price [1][6]. Company Developments - The company plans to seek priority review from the FDA to add IPF to the labeled indications for nebulized Tyvaso by the end of summer, based on results from the TETON-1 and TETON-2 studies, with no new safety concerns reported [2]. - Tyvaso is currently approved for treating pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease, and its potential approval for IPF could add an estimated $5.4 billion to United's revenue by 2033 [4]. Market Performance - United Therapeutics stock surged 17.6% to $615.00 in early trading, following the announcement, and previously closed at $522.83, just above a buy point of $519.99 [6]. - The stock's relative strength line is reaching new highs, and it holds a 98 IBD Composite Rating, ranking second in its industry group [7].